ACLARIS THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

20 Jan 2026 10:00:06 By NetDania Notify

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

12 Jan 2026 06:55:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

06 Jan 2026 06:59:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

19 Dec 2025 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

25 Nov 2025 08:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

06 Nov 2025 06:59:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

29 Oct 2025 07:30:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

30 Sep 2025 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

09 Sep 2025 07:00:08 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

27 Aug 2025 08:00:01 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

07 Aug 2025 06:59:33 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

29 Jul 2025 16:01:47 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Leadership Transition

28 Jul 2025 08:45:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

30 Jun 2025 09:31:48 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

26 Jun 2025 16:01:27 By Nasdaq GlobeNewswire

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

23 Jun 2025 06:59:36 By Nasdaq GlobeNewswire

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

02 Jun 2025 06:59:53 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

28 May 2025 09:20:15 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

09 May 2025 07:00:19 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

08 May 2025 06:50:51 By Nasdaq GlobeNewswire